Recorded Presentation from Optimizing Patient Outcomes - Targeted Therapies for Thyroid Carcinoma
Thyroid carcinoma is a rare disease; however, it is the seventh most common cancer diagnosed in those assigned female at birth. Greater attention to rare diseases is needed to improve treatment options in general, and specifically for anaplastic thyroid carcinoma.
Category
  • Thyroid Cancer
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Cost $0.00
Archived NCCN Tumor Boards: New Approaches to the Management of Resectable Non-Small Cell Lung Cancer
In recent years, several new systemic therapy regimens were approved by the FDA as additional neoadjuvant or adjuvant treatment options for eligible patients with resectable NSCLC and included in the NCCN Guidelines for NSCLC. Clinicians need to be aware of the updated treatment recommendations to ensure optimal outcomes for patients with early-stage NSCLC.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Cost $0.00
Archived NCCN Tumor Boards: Treatment Options and Navigating Sequencing of Therapies in Relapsed/Refractory Multiple Myeloma
With the introduction of many new therapies, the management of multiple myeloma is rapidly changing. A uniform treatment approach cannot be applied to all patients.
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Cost $0.00
NCCN Guidelines® Insights - Survivorship, Version 2.2025
These NCCN Guidelines Insights summarize the panel’s current recommendations and recent updates regarding physical activity, nutrition, and weight management for cancer survivors.
Category
  • Survivorship
Format
  • Monograph/Journal Supplement
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Cost $0.00
Advances in Antiemesis Management for Patients with Cancer
Recent clinical trials continue to enhance available data on the use of olanzapine for emesis prevention in parenteral anticancer agents with high and moderate emetogenic risk as well as for breakthrough treatment and an alternative to dexamethasone for delayed anticancer induced nausea/vomiting. Clinicians should be aware of these updates and how they apply to appropriate patients.
Category
  • Supportive Care Topics
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Cost $0.00
Updates in Metastatic Colorectal Cancer
As options for treatment of metastatic colorectal cancer evolve, clinicians can benefit from education about available options and criteria for selecting the appropriate option to offer their patients. An overview of these newer treatment options, and the data supporting these, should help clinicians better serve their patients with metastatic colorectal cancer.
Category
  • Colorectal Cancer
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Cost $0.00
Treatment Updates for Small Cell Lung Cancer
After decades of no change in treatment, practice changing therapies have now been added to the NCCN Guidelines for Small Cell Lung Cancer. This activity will help clinicians keep up to date with practice-changing strategies for SCLC.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
Cost $0.00
Plenary Session: Artificial Intelligence in Cancer Care: Opportunities, Challenges, and Governance
Education in this topic is important as AI is increasingly incorporated into care settings. Practitioners may not be aware of the way AI is currently being used or of its potential future application. Additionally, healthcare professionals need to be informed of the policy environment for the safe and effective use of AI in healthcare settings.
Category
  • Best Practices
Format
  • Recorded Webcast
Credits
  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 Participation
Cost $0.00
Artificial Intelligence: Evaluation and Success Criteria for AI Tools
With the promise of artificial intelligence (AI) and its potential to positively impact healthcare, comes the challenge of how to assess the feasibility and value associated with implementation of AI tools.
Category
  • Best Practices
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Cost $0.00
Improving Clinical Trial Accrual: Doing More with Less
Traditional recruitment to clinical trials was accomplished by outreach from the treating physician or staff associated with the clinical trial. It is important for clinicians to be aware of the logistics and the value that a clinical trial matching tool can bring to presenting a person with cancer the appropriate clinical trial.
Category
  • Best Practices
Format
  • Recorded Webcast
Credits
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
Cost $0.00

Pages